Market Overview

UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical on Value Inflection Outlook

Share:
Related BMRN
Is BioMarin Still An Outperform At This Research Firm?
BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Sanofi Misses on Q1 Earnings by a Penny, Maintains Outlook - Analyst Blog (Zacks)

Canaccord Genuity reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $52 to $56.

Canaccord Genuity noted, "We believe BMRN is at a key value inflection point as it enters 2013: a launch (GALNS), potential for three P3 programs (PEG-PAL in PKU, BMN-673 [PARP] in cancer and BMN-701 in Pompe) and clinical progress with two other drugs (BMN-190 in Batten disease [IND filing] and BMN-111 in achondroplasia enters P2), with details at the R&D day on Dec. 6 (highlighting ‘673 P1/2 data). While we are raising our price target to $56 (from $52), we note none of the pipeline ex-GALNS is included in our estimates – suggesting significant upside.

BioMarin Pharmaceutical closed at $37.41 on Friday.

Latest Ratings for BMRN

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Feb 2015CitigroupMaintainsBuy
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...